Clinical Research & Clinical Trials
Title |
Protocol |
Sponsor |
Study Status |
Clinical Research Coordinator |
|---|---|---|---|---|
A Randomized, Double-Blind, Double Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif®) In Patients With Relapsing Multiple Sclerosis |
WA21092/3 |
Genentech-Hoffman-LaRoche |
New Study, Enrollment Period TBA |
Angela Campbell |
JC Virus Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: The STRATIFY-2 Study |
101JC402 |
Biogen-Idec |
Study Active, Enrollment Ongoing |
Daniel Lebus |
Multicenter, randomized, double blind parallel group extension to study AC-058B202 to investigate the long term safety, tolerability, and efficacy of 10, 20 and 40 mg/day ACT-128800 (Ponesimod), an oral S1P1 receptor agonist, in patients with relapsing remitting Multiple Sclerosis |
|
Actelion |
Study Active, Enrollment Closed |
Angela Campbell |
A Phase III Randomized, Rater and Dose Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three Times weekly Subcutaneous Interferon Beta-1a in Patients with Relapsing Remitting Multiple Sclerosis who have Relapsed on Therapy |
CAMMS32400597 |
Genzyme Corporation; Cambridge, MA |
Study Active, Enrollment Closed |
Angela Campbell |
A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood Samples for Research Into the Causes of Multiple Sclerosis and Selected Demyelinating Diseases |
Stanford Protocol 17667 |
Accelerated Cure Project |
Study Active, Enrollment Ongoing |
Daniel Lebus |
Blood and CSF Repository to Identify Biomarkers in Multiple Sclerosis (in collaboration with May Han, MD; Stanford University; Stanford, CA) |
Stanford Protocol # 16691 |
unrestricted MS translational research training grant |
Study Active, Enrollment Ongoing |
Daniel Lebus |
Immune Modulation by Alemtuzumab in Multiple Sclerosis (in collaboration with Wendy Gilmore, PhD; USC; Los Angeles, CA): |
Stanford Protocol # 16988 |
|
Study Active, Enrollment Closed |
Angela Campbell |
An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab |
CAMMS03409 |
Genzyme Corporation; Cambridge, MA |
New Study, Enrollment Closed |
Angela Campbell |